N-glycan signatures identified in the serum from biliary tract cancer patients: Association with clinical diagnosis and prognosis.

Our NGFP technology supplements BTC diagnostics, distinguishing survival and recurrence subtypes for postoperative and immunotherapy, thereby supporting the development of treatment strategies.